Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small... ORIGINAL ARTICLE Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD,* Michael Peyton, PhD,* Yang Xie, PhD,†‡ Junichi Soh, MD,* John D. Minna, MD,*†§ Adi F. Gazdar, MD,*†¶ and Eugene P. Frenkel, MD†§ he epidermal growth factor receptor (EGFR) belongs to Introduction: Most epidermal growth factor receptor (EGFR) mu- Tthe EGFR family of tyrosine kinase receptors. Upon tant non-small cell lung cancers (NSCLCs) are sensitive to EGFR activation, EGFR can promote cell proliferation and survival tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, but through Ras/MEK/MAPK and/or PI3K/AKT signaling path- many EGFR wild type NSCLCs are resistant to TKIs. In this study, ways. In recent years, non-small cell lung cancers (NSCLCs) we examined the effects of the histone deacetylase inhibitor, ro- containing EGFR mutations have been found to be sensitive midepsin, in combination with erlotinib, in NSCLC cell lines and to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib xenografts. (Tarceva) or gefitinib (Iressa), and these drugs have been Methods: For in vitro studies, nine NSCLC cell lines with varying 3,4 successfully used in the therapy for such patients. Unfor- mutation status and histology were treated with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

Frenkel, Eugene P.
Journal of Thoracic Oncology , Volume 4 (2) – Feb 1, 2009
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/histone-deacetylase-inhibitor-romidepsin-enhances-anti-tumor-effect-of-e8K7JTr0bq

References (30)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318194fae7
pmid
19179890
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD,* Michael Peyton, PhD,* Yang Xie, PhD,†‡ Junichi Soh, MD,* John D. Minna, MD,*†§ Adi F. Gazdar, MD,*†¶ and Eugene P. Frenkel, MD†§ he epidermal growth factor receptor (EGFR) belongs to Introduction: Most epidermal growth factor receptor (EGFR) mu- Tthe EGFR family of tyrosine kinase receptors. Upon tant non-small cell lung cancers (NSCLCs) are sensitive to EGFR activation, EGFR can promote cell proliferation and survival tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, but through Ras/MEK/MAPK and/or PI3K/AKT signaling path- many EGFR wild type NSCLCs are resistant to TKIs. In this study, ways. In recent years, non-small cell lung cancers (NSCLCs) we examined the effects of the histone deacetylase inhibitor, ro- containing EGFR mutations have been found to be sensitive midepsin, in combination with erlotinib, in NSCLC cell lines and to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib xenografts. (Tarceva) or gefitinib (Iressa), and these drugs have been Methods: For in vitro studies, nine NSCLC cell lines with varying 3,4 successfully used in the therapy for such patients. Unfor- mutation status and histology were treated with

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Feb 1, 2009

There are no references for this article.